You are here: Home: Meet The Professors Vol. 1 2004: Case 1: Select publications
 |
| Select publications: Clinical use of trastuzumab |
 |
Burstein HJ et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19(10):2722-30. Abstract
Burstein HJ et al. Multicenter phase II study of trastuzumab (herceptin; H) and vinorelbine (navelbine; N) as first-line therapy for HER2 overexpressing metastatic breast cancer (HER2+ MBC). Proc ASCO 2002;Abstract#211.
Esteva FJ et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(7):1800-8. Abstract
Fountzilas G et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001;12(11):1545-51. Abstract
Jahanzeb M et al. Multicenter Phase II trial of weekly navelbine plus herceptin in chemonaive patients with HER2 positive metastatic breast carcinoma. Proc ASCO 2001;Abstract 1986.
Jahanzeb M et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002;7(5):410-7. Abstract
Meden H et al. Weekly intravenous recombinant humanized anti-Her2 monoclonal antibody (trastuzumab) plus docetaxel in patients with metastatic breast cancer (MBC): A pilot study. Proc ASCO 2001;Abstract 1987.
Miller KD et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2001;15(2 Suppl 3):38-40. Abstract
Perez EA et al. N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer: A North Central Cancer Treatment Group randomized phase II trial. Breast Cancer Res Treat 2003;Abstract 216.
Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22(2):322-9. Abstract
Pienkowski T et al. Taxotere, cisplatin and herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a Phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc ASCO 2001;Abstract 2030.
Raab G et al. Multicenter randomized phase II study of docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer (MBC). Breast Cancer Res Treat 2002;Abstract 443.
Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 35.
Seidman AD et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19(10):2587-95. Abstract
Slamon DJ et al. Phase II pilot study of herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-Neu proto-oncogene a pilot study of the UCLA Network. Proc ASCO 2001;Abstract 193.
Theodoulou M et al. TLC D99 (D, Myocet) and herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis. Proc ASCO 2002;Abstract 216
Uber KA et al. A Phase II trial of weekly docetaxel (D) and herceptin (H) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer. Proc ASCO 2001;Abstract 1949.
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
Vogel CL et al. Response to tamoxifen in estrogen receptor-poor metastatic breast cancer. Cancer 1987;6096):1184-9. Abstract
|
